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Background: Atherosclerosis is a well known progressive disease that recognizes risk factors 
such as diabetes, hypertension, smoking, dyslipidemia, and inflammation. Mechanisms underlying 
atherosclerotic processes during inflammation are not completely understood, but cytokines are 
also involved, in particular tumor necrosis factor-α (TNF-α). Chronic inflammatory diseases 
such as rheumatoid arthritis (RA) are commonly associated with atherosclerotic complication. 
Little is known about the role of treatment of chronic inflammatory disease on the evolution of 
atherosclerosis in this kind of disease. Usually, evolution of atherosclerosis is monitored by intima-
media thickness and the presence of plaques on several arteries such as common carotid.
Aim: The aim of the study was to monitor atherosclerosis evolution in seven RA patients on 
common treatment with infliximab (an anti-TNF-α drug) compared with seven RA patients 
during common treatment but not treated with infliximab.
Patients and methods: We selected 14 patients with RA according to the American College 
of Rheumatology classification criteria. Seven patients were selected before and after common 
treatment for RA based on nonsteroidal anti-inflammatory drugs (NSAIDs), methotrexate, 
and steroids (12 months), and seven patients before and after treatment based on infliximab 
associated with NSAIDs, methotrexate, and steroids (12 months). Ultrasound vascular imaging 
was performed to screen intima-media thickness and the presence of atherosclerotic plaques on 
common carotid artery and identify evolution of atherosclerosis.
Results: After 12 months, patients that were treated with infliximab showed significant 
worsening of atherosclerosis with an increase of intima-media thickness and the presence of 
further atherosclerotic plaques compared to patients that were treated traditionally and showed 
a nonsignificant increase of the same parameters.
Discussion: Treatment based on anti-TNF-α such as infliximab shows a worsening evolution 
of atherosclerosis based on our data. If these data are associated with a poor clinical outcome 
such as atherothrombosis of cerebral vessels and/or coronary vessels, this should be evaluated 
by further studies.
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Background
Atherosclerosis is a well known progressive disease with risk factors that were 
recognized by the Framingham study (ie, aging, hypercholesterolemia, hypertension, 
diabetes, smoking, and family history of atherothrombosis).1 Recently inflammation 
has been recognized as an additional atherosclerotic risk factor.2 Mechanisms under-
lying atherosclerotic processes during inflammation are not completely understood, 
but increased production of reactive oxygen species (ROS) seems to be involved and International Journal of General Medicine 2009:2 142
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seems to negatively interfere with reverse cholesterol 
transport and triggering atherosclerotic processes.3–5
Chronic inflammatory diseases such as rheumatoid 
arthritis (RA) are frequently associated with accelerated 
atherosclerosis6 and with severe clinical presentations.7 
Moreover, several markers of inflammation such as 
C-reactive protein (CRP) are frequently increased in patients 
with atherosclerosis. On the other hand, any cytokine 
is increased during inflammation and are involved in 
atherosclerotic processes. Some authors report increased 
levels of several cytokines during RA such as intercellular 
adhesion molecule-1 (ICAM-1), interleukin-6 (IL-6), and 
tumor necrosis factor-α (TNF-α).8–10
It is still unknown whether treatment of inflammatory 
disease may improve the prognosis of atherosclerotic com-
plication in patients with RA. In particular, data about the 
evolution of atherosclerosis in patients with RA taking ongo-
ing anti-TNF-α drugs such as infliximab are lacking.
This article evaluates the atherosclerotic evolution of 
patients with RA on ongoing treatment with infliximab 
compared to patients on ongoing common treatment by the 
evaluation of intima-media thickness (IMT) and/or the pres-
ence of atherothrombotic plaques on common carotid with 
ultrasound imaging.
Patients and methods
Patients
We selected 14 consecutive patients affected by RA accord-
ing to the American College of Rheumatology classification 
criteria. Patients were randomly divided into two different 
groups and assigned to two different treatment programs: 
group A included patients selected for therapy based on treat-
ment with nonsteroidal anti-inflammatory drugs (NSAIDs) 
on demand, steroids (per os, daily), methotrexate (intra-
muscular, weekly), and inflixmab (3 mg\kg at time 0 and 
every eight weeks for one year); group B acted as a control 
group and included patients selected for common treatment 
based on NSAIDs on demand, steroids (per os, daily), and 
methotrexate (intramuscular, weekly).
Group A included seven patients (six females and one 
male; median age, 56 years), while group B included seven 
patients (six females and one male; median age, 53 years).
Atherosclerosis evolution
Identification of atherosclerosis was performed with 
ultrasound imaging with a 7–10 Mhz linear probe (Vivid 4; 
GE Milan, Milan, Italy) in order to detect atherosclerotic 
plaques and the presence and the evolution of IMT. 
Ultrasound imaging was performed at the beginning of 
treatment (time 0) and after 12 months (time 1) of treatment 
for both groups.
Detection of IMT was performed three times on 
common carotid of both sides at the origin and at the bulb 
for all patients according to guidelines suggested by the 
Italian Society for Angiology and Vascular Medicine. The 
median value of three detections was considered as the main 
value.
The imaging evaluation was performed as a double-blind 
evaluation by two different physicians.
Clinical score
Disability related to RA for all patients was monitored 
according to the Health Assessment Questionnaire (HAQ) 
disability index11,12 and Disease Activity Score using 28 
joint counts (DAS 28)11,12 at the beginning and at the end of 
treatment (ie, time 0 and time 1).
Laboratory prognostic markers
Values of CRP were analyzed at time 0 and time 1 in order 
to have a laboratory follow-up screening of the evolution of 
RA in all selected patients in both groups.
Statistical analysis
Statistical analysis was performed with Student’s t-test for 
paired data. Data were considered to be significant if p value 
was  0.05.
Results
Our results are summarized in Table 1. We found an improve-
ment of clinical score (ie, DAS 28) in both groups at time 
0 and time 1, which was statistically significant (p = 0.04 
and p = 0.003, respectively).
Neither differences nor improvements were found in both 
groups for disability score (ie, HAQ) at time 0 and time 1, 
which was statistically nonsignificant (p = 0.3 and p = 0.3, 
respectively).
Levels of CRP were similar in both groups at time 0 and 
time 1, which was statistically nonsignificant (p = 0.8 and 
p = 0.1, respectively).
Patients from group A being treated by ongoing inf-
lixmab and common therapy (NSAIDs, steroids, and 
methotrexate), showed worsening IMT at time 1 compared 
to time 0, which was statistically significant, while patients 
from group B showed light worsening of IMT at time 1 
compared to time 0 and this value was not statistically 
significant.International Journal of General Medicine 2009:2 143
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Discussion
Patients affected by RA are more at risk of developing 
myocardial infarction and/or ischemic stroke when com-
pared to the general population13,14 because the presence 
of chronic inflammation associated with the possible 
presence of further atherothrombotic risk factors such 
as hypertension, diabetes, smoking, dyslipidemia, and 
family history of atherothrombosis. In recent years several 
biological drugs have been associated with common treat-
ment of chronic inflammatory disease such as RA, based 
on NSAIDs, steroids, and methotrexate.15 Prognosis, evalu-
ated by disability and activity score, seems to be better for 
patients who have added biological drugs (ie, inflixmab, 
etanercept, adalimumab, anakinra, etc)16 to traditional 
therapy.
Infliximab, an anti-TNF-α drug, is one of the most 
common biological drugs used for the treatment of RA.16 
Treatment based on the administration of infliximab showed 
several improvements in the prognosis of RA, in particular 
advantages were found in several reports for disability 
index (eg, HAQ) and also for the disease activity score 
(eg, DAS 28).16 Improvements were discovered not only 
on the global assessment, on the evolution of pain, and on 
fatigue, but also for serological markers such as improve-
ment of CRP levels and for the improvement of endothelial 
dysfunction.17–19 However, several side effects of treat-
ment based on infliximab were reported. A higher risk a 
priori of infection development20,21 has been underlined by 
several reports as the risk of recurrence of herpes zoster.22 
Furthermore, from a cardiovascular point of view, several 
side effects have been reported for patients in ongoing treat-
ment with infliximab such as congestive heart failure23,24 and 
an unassociated improvement of arterial stiffness.16
Data about the evolution of atherosclerosis for patients 
in ongoing treatment with infliximab are lacking in the 
literature. Our data showed an improvement of clinical 
parameters evaluated with the DAS 28 score for both 
groups with RA. On the other hand, no different values were 
discovered in both groups when we consider the disability 
index (ie, HAQ) and CRP levels at times 0 and 1. Further 
data regarding the clinical follow-up of chronic inflamma-
tory disease are lacking in our study and this aspect may be 
considered as a partial study limitation.
However, the aim of our study is to focus on the evolu-
tion of the atherosclerosis in patients with RA treated or 
untreated with infliximab. Interestingly, patients with RA 
treated with infliximab showed worsening of asymptomatic 
atherosclerosis analyzed by IMT and increasing evidence of 
atherosclerotic plaques while the increase of IMT for patients 
with RA treated with traditional drugs (ie, without infliximab) 
was slight. We may speculate that the worsening of athero-
sclerosis in group A may be related to the possible influence 
of other traditional atherosclerotic risk factors that have not 
been considered in our report. However, although data on the 
influence of traditional atherosclerotic risk factors are lack-
ing and actually should be considered as a study limitation, 
we should consider two further relevant aspects: first of all, 
we should relate this aspect to the altered metabolism of 
lipoprotein during treatment with infliximab that has been 
reported in the literature,25,26 but we may also consider that 
the natural history of RA, in particular its mortality, seems 
to be influenced mainly by atherothrombosis.27 Therefore, 
for this reason, patients treated with inflixmab may show a 
more advanced increase in IMT and asymptomatic plaques. 
We may speculate on the adverse cardiovascular outcome of 
such patients with RA treated with infliximab and this could 
also be in agreement with previous reports that reported an 
increased incidence of heart failure during treatment. It is 
not clear whether this aspect of treatment based on inflixmab 
may be a class effect or a dose-dependent effect or may be 
associated with an increased incidence of atherothrombosis 
of in any vascular region is not clear and should be evaluated 
by further prospective studies focusing on the incidences of 
thrombotic events.
Table 1 Clinical, imaging and laboratory follow up of patient with RA
Group A Group B
Time 0 Time 1 p Time 0 Time 1 p Normal values
IMT (mm) 0.84 ± 0.27 1.17 ± 0.39 0.026, s 1.07 ± 0.25 1.13 ± 0.24 0.2, ns 0.07
DAS 28 7.0 ± 1.4 4.8 ± 2.0 0.04, s 6.4 ± 1.25 4.9 ± 1.96 0.003, ns
HAQ 1.78 ± 0.75 1.41 ± 0.67 0.3, ns 1.36 ± 0.64 1.11 ± 0.74 0.3, ns
PCR (mg\dL) 2.54 ± 1.99 2.42 ± 2.79 0.8, ns 2.16 ± 2.10 1.45 ± 2.05 0.1, ns 0.0–1.0
Abbreviations: DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; IMT, intima-media thickness; ns, not significant; PCR, polymerase chain reaction; 
RA, rheumatoid arthritis.International Journal of General Medicine 2009:2
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